Zone 1 主动脉弓杂交腔内修复联合解剖外旁路的荟萃分析
本荟萃分析纳入20项研究共348例主动脉弓疾病患者,评估避免正中开胸和体外循环的解剖外旁路联合同期或分期Zone 1杂交腔内修复的疗效。结果显示院内或30天死亡率为10.1%,1年生存率77.2%,结论认为Zone 1杂交修复的短期和长期结局可接受,可作为主动脉弓疾病的替代方案。
要点
- Zone 1杂交修复院内或30天死亡率为10.1%,总体技术成功率为89.8%。
- 早期1型内漏率为14.0%,卒中为9.5%,脊髓截瘫为3.8%。
- 术后1年生存率为77.2%,4年以上生存率为65.9%。
核心结论
- Zone 1杂交修复在短期和长期发病率及死亡率方面结局令人满意,可考虑作为主动脉弓疾病的替代方法。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane数据库,纳入20项研究共348例接受Zone 1杂交弓修复的成人患者,采用随机效应模型分析。
主要发现
- 院内或30天死亡率为10.1%(95%CI 6.7-14.9%)。
- 总体手术技术成功率为89.8%(95%CI 83.7-93.8%)。
- 早期1型内漏率为14.0%(95%CI 7.4-24.7%),卒中为9.5%(95%CI 6.1-14.3%),脊髓截瘫为3.8%(95%CI 1.9-7.6%),逆行性主动脉夹层为4.1%(95%CI 1.5-10.6%)。
- 术后1年生存率为77.2%(95%CI 66.1-85.4%),3年生存率为73.7%(95%CI 59.2-84.4%),4年以上(范围58-80个月)生存率为65.9%(95%CI 53.6-76.4%)。
- 晚期1型内漏率为11.8%(95%CI 5.5-23.7%),总体再干预率为11.6%(95%CI 6.4-20.1%)。
临床怎么用
- 对于主动脉弓疾病患者,Zone 1杂交修复联合解剖外旁路可作为避免正中开胸和体外循环的替代治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this meta-analysis is to determine the morbidity and mortality outcomes of adult patients with aortic arch disease managed with extra-anatomical bypass avoiding median sternotomy and cardiopulmonary bypass, with simultaneous or staged hybrid zone 1 endovascular aortic repair. METHODS: Systematic literature searches of the MEDLINE, EMBASE, and Cochrane databases were carried out to identify relevant studies on zone 1 hybrid arch repair. Extracted data were analyzed by random effects models. Primary outcomes included 30-day or in-hospital mortality. Longitudinal survival was analyzed up to 7 years from date of operation. Secondary outcomes included in-hospital morbidity, as well as late endoleak and reintervention. RESULTS: Twenty studies incorporating 348 patients were included. In-hospital or 30-day mortality was 10.1% (95% confidence interval, 6.7-14.9%). Overall operative technical success was 89.8% (83.7-93.8%). Early type 1 endoleak rate was 14.0% (7.4-24.7%). Stroke prevalence was 9.5% (6.1-14.3%). Spinal cord paraplegia prevalence was 3.8% (1.9-7.6%). Retrograde aortic dissection prevalence was 4.1% (1.5-10.6%). Survival at 1 year postoperatively was 77.2% (66.1-85.4%). Survival at 3 years postoperatively was 73.7% (59.2-84.4%). Survival beyond 4 years postoperatively (range 58-80 months) was 65.9% (53.6-76.4%). Late type 1 endoleak prevalence was 11.8% (5.5-23.7%). Overall rate of reintervention was 11.6% (6.4-20.1%). CONCLUSIONS: Zone 1 hybrid repair has evidence for satisfactory short- and long-term morbidity/mortality outcomes and may be considered as an alternative approach to aortic arch disease.
引用
- Bayfield NG, Samuel M, Bayfield AE, et al. Zone 1 Aortic Arch Hybrid Endovascular Repair with Extra-anatomical Bypass: A Meta-analysis. Ann Vasc Surg. 2020. PMID: 33227479. doi:10.1016/j.avsg.2020.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。